{"id":"W2094295731","doi":"10.1002/cam4.363","title":"A phase <scp>2</scp>, multicenter, open‐label study of sepantronium bromide (<scp>YM</scp>155) plus docetaxel in patients with stage <scp>III</scp> (unresectable) or stage <scp>IV</scp> melanoma","year":2014,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Docetaxel; Medicine; Clinical endpoint; Survivin; Melanoma; Phases of clinical research; Internal medicine; Gastroenterology; Oncology; Chemotherapy; Cancer; Cancer research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002147791,0.001446571,0.003157326,0.0009601491,0.0006653153,0.0001417235,0.00238282,0.0007816689,0.0002634684],"category_scores_gemma":[0.004368719,0.001119812,0.0001989893,0.001425567,0.00130183,0.0008764918,0.000774671,0.001799662,0.0001423371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006301547,"about_ca_system_score_gemma":0.001008811,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008303643,"about_ca_topic_score_gemma":0.004079643,"domain_scores_codex":[0.9907252,0.002023079,0.002265766,0.001792254,0.0006370231,0.002556679],"domain_scores_gemma":[0.9892833,0.005892816,0.00176559,0.002050658,0.0007059986,0.0003016905],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0150236,0.04936764,0.2187587,0.002232549,0.0130027,0.0006460637,0.1369862,0.0004879964,0.4213933,0.0002476849,0.1239702,0.01788336],"study_design_scores_gemma":[0.3464979,0.03505209,0.07218429,0.002124799,0.001092763,0.00004962164,0.0511704,0.0002944933,0.07250538,0.00001853376,0.4186721,0.0003376456],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9685668,0.02140978,0.0002459082,0.00006415701,0.002477518,0.004773971,0.0005973313,0.0001868088,0.001677736],"genre_scores_gemma":[0.9109144,0.001587845,0.00007451843,0.0009053966,0.000244659,0.000754223,0.0005455893,0.0002602479,0.08471309],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3488879,"threshold_uncertainty_score":0.9998284,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02586138156546244,"score_gpt":0.309311015578034,"score_spread":0.2834496340125715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}